Skip to main content

Exobiology



According to a new calculation by Alexei Sharov and Richard Gordon, life must have pre-existed the planet Earth.

You can find the study here.  You can find some of my own earlier uncredentialed speculations about related matters here.

Sharov and Gordon are both properly credentialed. Each is a Ph.D. with a research role with prestigious (though non-academic) institutions. Nonetheless, there is a good deal of speculation in their work, as one might imagine given the subject.

The gist is that they infer that genetic complexity increased at an exponential pace: it doubles every 376 million years.  If that is right, then life originated roughly 9.7 billion years ago (give or take 2.5 billion). And if that is right then it could not have originated on earth. Radiometric dating puts the age of the earth at roughly 4.5 billion years.

So on their guesstimations, life must have been already 5 billion years old before the earth was formed.

Their calculations also indicate that it would have taken life 5 billion years to reach the degree of genetic complexity present in a bacterium. Five billion years, counting forward from the hypothetical date of origin 9.7 billion years ago, allows for the possibility that bacteria drifted onto the new planet Earth and began their history of development/adaptations here.

I applaud the direction of their thinking, as it confirms my prejudices, which is always the best test of science.




Comments

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…